MinterEllison advises AusCann on acquisition of CannPal Animal Therapeutics Limited

1 minute read  18.11.2020

The acquisition will expand AusCann's market while maintaining its focus and expertise in cannabinoid therapeutics.

 

MinterEllison has advised AusCann Group Holdings Ltd (AusCann) on its all scrip acquisition of CannPal Animal Therapeutics Limited (CannPal).

AusCann has entered into a scheme implementation deed with CannPal, where AusCann will acquire 100% of the issued share capital in CannPal under a scheme of arrangement. AusCann will own 100% of CannPal shares on implementation of the scheme and CannPal shareholders will receive 1.3 AusCann shares for every 1 CannPal share.

MinterEllison advised AusCann on all aspects of the approach, structuring, due diligence and negotiation of the scheme implementation deed.

"We are pleased to have assisted AusCann in this merger within a challenging environment, where both listed companies were affected by the market volatility impacting organisations around the globe," said lead partner Bart Oude-Vrielink.

"The acquisition provides a positive outcome for AusCann, where it can expand its own market while maintaining its focus and expertise in cannabinoid therapeutics. It also provides them with scope to develop new therapeutic products with the potential to generate new product and licensing revenues. 

"During a period of time where healthcare is such an important focus for our society, we're delighted to support AusCann in their mission to provide greater medical treatment options for the Australian community," Mr Oude-Vrielink added.

Kidder Williams acted as financial adviser to AusCann.

Mr Oude-Vrielink and Sudharshan Senathirajah led the MinterEllison team and were supported by Mark Simkiss, Josh Carfi and other specialist team members.

Related lawyers

Tags

For media enquiries, please contact:

Charlotte Juhasz
Director, Corporate Communications & Media
M +61 408 837 975

eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJuYW1laWQiOiI4MjZmZGZiNC0yYWU0LTRiMjAtYTJmMS0zMDVjMDEwZjhiY2QiLCJyb2xlIjoiQXBpVXNlciIsIm5iZiI6MTczMDgzNzc5MywiZXhwIjoxNzMwODM4OTkzLCJpYXQiOjE3MzA4Mzc3OTMsImlzcyI6Imh0dHBzOi8vd3d3Lm1pbnRlcmVsbGlzb24uY29tL2FydGljbGVzL2FkdmlzZWQtYXVzY2Fubi1vbi1hY3F1aXNpdGlvbi1vZi1jYW5ucGFsLWFuaW1hbC10aGVyYXBldXRpY3MtbGltaXRlZCIsImF1ZCI6Imh0dHBzOi8vd3d3Lm1pbnRlcmVsbGlzb24uY29tL2FydGljbGVzL2FkdmlzZWQtYXVzY2Fubi1vbi1hY3F1aXNpdGlvbi1vZi1jYW5ucGFsLWFuaW1hbC10aGVyYXBldXRpY3MtbGltaXRlZCJ9.V-8JrExAwu26IHifdqXtXPGhRXgfhEY7065lxAn3Svo
https://www.minterellison.com/articles/advised-auscann-on-acquisition-of-cannpal-animal-therapeutics-limited

Point of View: insights into key issues and challenges facing business today.

In this series of interviews with MinterEllison partners we hear their perspective on key areas of interest to our clients and the business community.